Literature DB >> 33082079

Idiopathic pulmonary arterial hypertension phenotypes determined by cluster analysis from the COMPERA registry.

Marius M Hoeper1, Christine Pausch2, Ekkehard Grünig3, Hans Klose4, Gerd Staehler5, Doerte Huscher6, David Pittrow7, Karen M Olsson8, Carmine Dario Vizza9, Henning Gall10, Nicola Benjamin3, Oliver Distler11, Christian Opitz12, J Simon R Gibbs13, Marion Delcroix14, H Ardeschir Ghofrani15, Stephan Rosenkranz16, Ralf Ewert17, Harald Kaemmerer18, Tobias J Lange19, Hans-Joachim Kabitz20, Dirk Skowasch21, Andris Skride22, Elena Jureviciene23, Egle Paleviciute23, Skaidrius Miliauskas24, Martin Claussen25, Juergen Behr26, Katrin Milger27, Michael Halank28, Heinrike Wilkens29, Hubert Wirtz30, Elena Pfeuffer-Jovic31, Lars Harbaum4, Werner Scholtz32, Daniel Dumitrescu32, Leonhard Bruch33, Gerry Coghlan34, Claus Neurohr35, Iraklis Tsangaris36, Matthias Gorenflo37, Laura Scelsi38, Anton Vonk-Noordegraaf39, Silvia Ulrich40, Matthias Held32.   

Abstract

The term idiopathic pulmonary arterial hypertension (IPAH) is used to categorize patients with pre-capillary pulmonary hypertension of unknown origin. There is considerable variability in the clinical presentation of these patients. Using data from the Comparative, Prospective Registry of Newly Initiated Therapies for Pulmonary Hypertension, we performed a cluster analysis of 841 patients with IPAH based on age, sex, diffusion capacity of the lung for carbon monoxide (DLCO; <45% vs ≥45% predicted), smoking status, and presence of comorbidities (obesity, hypertension, coronary heart disease, and diabetes mellitus). A hierarchical agglomerative clustering algorithm was performed using Ward's minimum variance method. The clusters were analyzed in terms of baseline characteristics; survival; and response to pulmonary arterial hypertension (PAH) therapy, expressed as changes from baseline to follow-up in functional class, 6-minute walking distance, cardiac biomarkers, and risk. Three clusters were identified: Cluster 1 (n = 106; 12.6%): median age 45 years, 76% females, no comorbidities, mostly never smokers, DLCO ≥45%; Cluster 2 (n = 301; 35.8%): median age 75 years, 98% females, frequent comorbidities, no smoking history, DLCO mostly ≥45%; and Cluster 3 (n = 434; 51.6%): median age 72 years, 72% males, frequent comorbidities, history of smoking, and low DLCO. Patients in Cluster 1 had a better response to PAH treatment than patients in the 2 other clusters. Survival over 5 years was 84.6% in Cluster 1, 59.2% in Cluster 2, and 42.2% in Cluster 3 (unadjusted p < 0.001 for comparison between all groups). The population of patients diagnosed with IPAH is heterogenous. This cluster analysis identified distinct phenotypes, which differed in clinical presentation, response to therapy, and survival.
Copyright © 2020 The Authors. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  cluster; mortality; phenotypes; pulmonary arterial hypertension; survival

Year:  2020        PMID: 33082079     DOI: 10.1016/j.healun.2020.09.011

Source DB:  PubMed          Journal:  J Heart Lung Transplant        ISSN: 1053-2498            Impact factor:   10.247


  19 in total

Review 1.  'There and Back Again'-Forward Genetics and Reverse Phenotyping in Pulmonary Arterial Hypertension.

Authors:  Emilia M Swietlik; Matina Prapa; Jennifer M Martin; Divya Pandya; Kathryn Auckland; Nicholas W Morrell; Stefan Gräf
Journal:  Genes (Basel)       Date:  2020-11-26       Impact factor: 4.096

2.  Finding Pulmonary Arterial Hypertension-Switching to Offense to Mitigate Disease Burden.

Authors:  Bradley A Maron; Marc Humbert
Journal:  JAMA Cardiol       Date:  2022-04-01       Impact factor: 30.154

3.  The Right Ventricular-Pulmonary Arterial Coupling and Diastolic Function Response to Therapy in Pulmonary Arterial Hypertension.

Authors:  Rebecca R Vanderpool; Kendall S Hunter; Michael Insel; Joe G N Garcia; Edward J Bedrick; Ryan J Tedford; Franz P Rischard
Journal:  Chest       Date:  2021-10-09       Impact factor: 10.262

4.  The impact of comorbidities on selexipag treatment effect in patients with pulmonary arterial hypertension: insights from the GRIPHON study.

Authors:  Stephan Rosenkranz; Richard Channick; Kelly M Chin; Bartosz Jenner; Sean Gaine; Nazzareno Galiè; Hossein-Ardeschir Ghofrani; Marius M Hoeper; Vallerie V McLaughlin; Camille Du Roure; Lewis J Rubin; Olivier Sitbon; Victor Tapson; Irene M Lang
Journal:  Eur J Heart Fail       Date:  2021-11-21       Impact factor: 17.349

Review 5.  The physiological basis of pulmonary arterial hypertension.

Authors:  Robert Naeije; Manuel J Richter; Lewis J Rubin
Journal:  Eur Respir J       Date:  2022-06-16       Impact factor: 33.795

6.  Monotherapy in patients with pulmonary arterial hypertension at four German PH centres.

Authors:  Beate Stubbe; Hans-Jürgen Seyfarth; Janina Kleymann; Michael Halank; Hussam Al Ghorani; Anne Obst; Susanna Desole; Ralf Ewert; Christian F Opitz
Journal:  BMC Pulm Med       Date:  2021-04-21       Impact factor: 3.317

7.  Computed tomography lung parenchymal descriptions in routine radiological reporting have diagnostic and prognostic utility in patients with idiopathic pulmonary arterial hypertension and pulmonary hypertension associated with lung disease.

Authors:  Krit Dwivedi; Robin Condliffe; Michael Sharkey; Robert Lewis; Samer Alabed; Smitha Rajaram; Catherine Hill; Laura Saunders; Peter Metherall; Faisal Alandejani; Dheyaa Alkhanfar; Jim M Wild; Haiping Lu; David G Kiely; Andrew J Swift
Journal:  ERJ Open Res       Date:  2022-01-24

8.  Carbon Monoxide Diffusion Capacity as a Severity Marker in Pulmonary Hypertension.

Authors:  Eleni Diamanti; Vasiliki Karava; Patrick Yerly; John David Aubert
Journal:  J Clin Med       Date:  2021-12-27       Impact factor: 4.241

Review 9.  New Insights into Pulmonary Hypertension: A Role for Connexin-Mediated Signalling.

Authors:  Myo Htet; Jane E Nally; Patricia E Martin; Yvonne Dempsie
Journal:  Int J Mol Sci       Date:  2021-12-29       Impact factor: 5.923

10.  Early risk prediction in idiopathic versus connective tissue disease-associated pulmonary arterial hypertension: call for a refined assessment.

Authors:  Clara Hjalmarsson; Barbro Kjellström; Kjell Jansson; Magnus Nisell; David Kylhammar; Mohammad Kavianipour; Göran Rådegran; Stefan Söderberg; Gerhard Wikström; Dirk M Wuttge; Roger Hesselstrand
Journal:  ERJ Open Res       Date:  2021-08-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.